Early Identification and Management of Patients with Rash on Apalutamide

Authored by Alison Birtle, published on 2026-04-20 20:02:35.0

  1. Patient on apalutamide presents with rash
    • Determine cause of rash
      • If other cause identified, treat according to aetiology (if cause unclear, refer to dermatology)* If other causes excluded, manage as ADR and grade rash using NCI-CTCAE.
        • Grade 1
          • Continue apalutamide at the same dose
            • Monitor for change in severity every 5–7 days
              • If rash is stable or improving, continue current treatment until rash resolves
              • If rash worsens or does not improve, follow guidance for Grade 3 and refer to a dermatologist*
                • Pause apalutamide until rash is Grade ≤1
                  • Monitor for change in severity every 5–7 days
                    • If rash improves to Grade 2, continue current management
                      • Monitor at least once per week
                        • If rash improves to Grade ≤1
                        • If rash is the same or has worsened, refer to a dermatologist*
                    • If rash is the same or has worsened, refer to a dermatologist*
                    • If rash improves to Grade ≤1
        • Grade 2
          • Continue apalutamide at the same dose
            • Monitor for change in severity every 5–7 days
              • If rash is stable or improving, continue current treatment until rash resolves
              • If rash worsens or does not improve, follow guidance for Grade 3 and refer to a dermatologist*
                • Pause apalutamide until rash is Grade ≤1
                  • Monitor for change in severity every 5–7 days
                    • If rash improves to Grade 2, continue current management
                      • Monitor at least once per week
                        • If rash improves to Grade ≤1
                        • If rash is the same or has worsened, refer to a dermatologist*
                    • If rash is the same or has worsened, refer to a dermatologist*
                    • If rash improves to Grade ≤1
        • Grade 3 (If signs of DRESS/SJS/TEN, refer to dermatology)*
          • Pause apalutamide until rash is Grade ≤1
            • Monitor for change in severity every 5–7 days
              • If rash improves to Grade 2, continue current management
                • Monitor at least once per week
                  • If rash improves to Grade ≤1
                  • If rash is the same or has worsened, refer to a dermatologist*
              • If rash is the same or has worsened, refer to a dermatologist*
              • If rash improves to Grade ≤1
  2. Information for patients starting apalutamide
tosprivacyEarly Identification and Management of Patients with Rash on ApalutamideApalutamide Treatment and Metastasis-free Survival in Prostate CancerApalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyApalutamide and Overall Survival in Prostate CancerApalutamide for Metastatic, Castration-Sensitive Prostate CancerDermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor ApalutamideDrug reaction with eosinophilia and systemic symptoms with features resembling Stevens-Johnson syndrome/toxic epidermal necrolysis related to apalutamideImpact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP studyApalutamide-Induced Toxic Epidermal Necrolysis in a Caucasian Patient with Metastatic Castration-Sensitive Prostate Cancer: A Case Report and Review of the Literature